The Latest Cardiac and Vascular News
PONTE VEDRA, Fla., March 30, 2023 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, […]
Conference Call Scheduled for Today at 8:30 a.m. Eastern Time BERKELEY HEIGHTS, N.J., March 30, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for the fourth […]
Progress continued on the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) Expanded intellectual property portfolio with four issued patents in 2022 Management team strengthened and expanded in 2022 Sufficiently funded into second half of 2025 WALTHAM, Mass., March 29, 2023 (GLOBE NEWSWIRE) — Aerovate […]
– 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 – – Resumed shipments of CGuard EPS to CE Mark territories under the pre-existing Medical Device Directive (MDD) regulatory framework; Company anticipates re-certification under new Medical Device Regulation (MRD) framework in coming weeks – – Continued enrollment in the C-Guardian […]
Fiscal Year 2023 Third Quarter Highlights Net sales of $80.7 million increased 9.1% compared to the prior-year quarter Med Tech net sales of $22.9 million increased 16.6% Med Device net sales of $57.8 million increased 6.4% Gross margin of 50.2% decreased 200 basis points year over year GAAP loss per […]
FREMONT, CA / ACCESSWIRE / March 28, 2023 / Q’Apel Medical Inc. was granted the CE Mark under MDR for Walrus, their U.S. market-leading Balloon Guide Catheter (BGC) utilized in treating patients suffering an acute ischemic stroke. The Walrus BGC has been utilized by Neuro Interventional physicians since 2019 and has successfully treated over 20,000 […]
– Year-end cash resources, together with $125 million proceeds from March 2023 strategic financing, expected to fund operations into mid-2025 – NDA submission for etripamil in patients with PSVT expected for 3Q23 MONTREAL and CHARLOTTE, N.C., March 29, 2023 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results […]
SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2022 and filed its annual report on Form 10-K for the year ended December 31, […]
Announces Receipt of Positive Formal FDA Feedback via the Q-Submission Program Substantially reduces the anticipated time and cost needed to receive a PMA EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that it has […]
ECGenius System & CARDIALYTICS Suite Recognized as Critical to the Evolution of Electrophysiology COPENHAGEN, Denmark, March 28, 2023 /PRNewswire/ — CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision-making in the EP lab, is proud to announce the achievement of significant milestones demonstrating both the clinical and commercial […]
